Sir,
We thank Tian et al (2015) for their comments on our paper (Korn et al, 2015). They appear to agree with us that their analytic methods proposed in Tian et al (2014) do not work unless the following two assumptions hold: (1) the treatments have approximately equal efficacy in the overall population; and (2) the treatments the patients received were essentially assigned randomly (and not associated with factors that have prognostic importance). We note that these two assumptions are very strong, and, following Tian et al (2015), we review their plausibility in the context of recurrent ovarian cancer considered by Rutherford et al (2013). For assumption (1), one might question whether single-agent cisplatin or carboplatin works as well as the other treatments (e.g., combinations with platinum) on the population studied by Rutherford et al (2013), which contains ∼45% of patients who were resistant to their initial platinum chemotherapy. If single-agent platinum drugs do not work as well, then assumption (1) is violated.
Assumption (2) allows one to treat observational data as if it were from a randomised clinical trial. It is impossible to prove that this assumption is satisfied, as there may always be important unmeasured prognostic characteristics of the patients that clinicians are implicitly using to help decide which treatments have to be given to which patients. However, it is possible to show that the assumption is questionable by finding a known important prognostic variable that is associated with the treatment the patients received. In the present case, consider the recognised important prognostic variable defined by whether patients are platinum sensitive or platinum resistant to their initial platinum chemotherapy (Jayson et al, 2014). It is known that patients with platinum-sensitive recurrent disease are more likely to be treated with combination of drugs including a platinum agent, whereas patients with platinum-resistant recurrent disease are more likely treated with a single (non-platinum) drug (Jayson et al, 2014). Indeed, this appears to be the case with data analysed by Rutherford et al (2013), where 27% of the platinum-sensitive patients received (non-platinum) single drugs whereas 50% of the platinum-resistant patients did (Table 1). This suggests a violation of assumption (2) that patients had their treatment chosen randomly.
It can be difficult to assess in any given clinical situation whether the required assumptions for the analytic methods of Tian et al (2014) are reasonable. In particular, the required assumptions seem questionable in this recurrent ovarian cancer setting.
References
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 284: 1376–1388.
Korn EL, Freidlin B (2015) Evaluation of chemoresponse assays as predictive markers. Br J Cancer 112: 621–623.
Rutherford T, Orr J Jr, Grendys E Jr, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ (2013) A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol 131: 362–367.
Tian C, Gabrin MJ, Brower SL, Sargent DJ (2015) Comment on ‘Evaluation of chemoresponse assays as pedictive markers’. Br J Cancer e-pub ahead of print 17 February 2015 doi:10.1038/bjc.2014.661.
Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL (2014) Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. Br J Cancer 111: 843–850.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
About this article
Cite this article
Korn, E., Freidlin, B. Response to Comment on: ‘Evaluation of chemoresponse assays as predictive biomarkers’. Br J Cancer 112, 1978 (2015). https://doi.org/10.1038/bjc.2015.157
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2015.157